- Home
- FLYE vs HSCS Comparison
FLYE vs HSCS Comparison
Compare FLYE & HSCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FLYE | HSCS |
|---|---|---|
| Founded | 2018 | 2007 |
| Country | United States | United States |
| Employees | N/A | 12 |
| Industry | Aerospace | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5M | 8.2M |
| IPO Year | 2024 | N/A |
Fundamental Metrics
Financial Performance| Metric | FLYE | HSCS |
|---|---|---|
| Price | $2.42 | $2.46 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | ★ 10.1K | 8.9K |
| Earning Date | 03-19-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $25,427,163.00 | N/A |
| Revenue This Year | N/A | $1,072.41 |
| Revenue Next Year | N/A | $2,700.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.33 | $2.01 |
| 52 Week High | $21.80 | $6.47 |
Technical Indicators
Market Signals| Indicator | FLYE | HSCS |
|---|---|---|
| Relative Strength Index (RSI) | 50.96 | 38.41 |
| Support Level | $1.74 | $2.09 |
| Resistance Level | $5.87 | $3.72 |
| Average True Range (ATR) | 0.15 | 0.18 |
| MACD | 0.14 | -0.00 |
| Stochastic Oscillator | 74.72 | 28.12 |
Price Performance
Historical ComparisonAbout FLYE Fly-E Group Inc.
Fly-E Group Inc is an electric vehicle company that is principally engaged in designing, installing and selling smart electric motorcycles, electric bikes, electric scooters and related accessories under the brand Fly E-Bike. It also provides connectivity solutions and value-added services to their customers.
About HSCS Heart Test Laboratories Inc.
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.